Challenges in Pediatric Endocrinology
Endocrine and Diabetes Research Unit, Schneider Children’s Medical Center, Tel Aviv University, Petah Tikva 49200, Israel
Children 2023, 10(11), 1757; https://doi.org/10.3390/children10111757
Submission received: 23 October 2023
/
Accepted: 23 October 2023
/
Published: 30 October 2023
(This article belongs to the Section Pediatric Endocrinology)
As the Section Editor-in-Chief, it is my pleasure to introduce the new section of Children devoted to pediatric endocrinology. Its scope is to publish original academic articles, reviews, and special editions on achievements in ongoing basic and clinical research in endocrinology, diabetes, metabolism, genetics and to review the effects of new drugs designed to prevent or treat diseases in those fields.
Pediatric endocrinology became a separate discipline in the 1940s due to the work of Lawson Wilkins in Baltimore and Nathan Talbot in Boston [1], who also published the first textbooks on this topic in 1950 [2] and 1952, respectively [3].
Since then, technological advancements, using biochemical and genetic methods, have enabled the disclosure of the molecular mechanisms of many clinically recognized diseases and the discovery of new ones [4,5,6]. During this period, the norms for growth and the basis of pediatric endocrinology were designed [7].
However, despite the substantial knowledge accumulated, there remain many challenging questions to be answered. Below are a few examples.
Many mechanisms causing abnormal growth, such as the etiology of idiopathic short stature [8,9,10], overgrowth [11], or growth without growth hormone [12], are still uncertain. Of great concern are the continuous increases in the worldwide incidences of Type I diabetes [13], obesity, and Type II diabetes [14].
Preventive interventions in Type I childhood diabetes have failed so far, and there is no cure [15]. The increasing numbers of youth in many countries with gender dysphoria or sex development present many diagnostic and therapeutic problems [16,17,18].
Newly designed growth-stimulating drugs such as long acting growth hormone preparations or novel approaches for the treatment of achondroplasia [19,20] will need close follow-up for their efficacy and early or late adverse effects.
Our new section will strive to follow new research in all aspects of pediatric endocrinology and disseminate the results to pediatric endocrinologists, neonatologists, geneticists, and pediatricians in practice.
Conflicts of Interest
The author declares no conflict of interest.
References
- Fisher, D.A.; Laron, Z. The Early History of Pediatric—Endocrinology. Pediatr. Endocrinol. Rev. 2003, 1 (Suppl. S1), 66–91. [Google Scholar] [PubMed]
- Wilkins, L. The Diagnosis and Treatment of Endocrine Disorders in Childhood and Adolescence; Charles C Thomas: Springfield, IL, USA, 1950. [Google Scholar]
- Talbot, N.B.; Sobei, E.H.; McArthur, J.W.; Crawford, J.D. Functional Endocrinology from Birth through Adolescence; Harvard University Press: Cambridge, UK, 1952. [Google Scholar]
- Argente, J. Genetic Causes of Growth Disorders. Curr. Opin. Endocr. Metab. Res. 2020, 14, 7–14. [Google Scholar] [CrossRef]
- Wit, J.M.; Oostdijk, W.; Losekoot, M.; van Duyvenvoorde, H.A.; Ruivenkamp, C.A.; Kant, S.G. Mechanisms in Endocrinology: Novel Genetic causes of short stature. Eur. J. Endocrinol. 2016, 174, R145–R173. [Google Scholar] [CrossRef] [PubMed]
- Laron, Z. Laron syndrome (primary growth hormone resistance or insensitivity): The personal experience 1958–2003. J. Clin. Endocrinol. Metab. 2004, 89, 1031–1044. [Google Scholar] [CrossRef] [PubMed]
- Tanner, J.M. Foetus into Man Physical Growth Conception to Maturity, 2nd ed.; Castlemead Publications: Hertfordshire, UK, 1989. [Google Scholar]
- Homma, T.K.; Krepischi, A.C.; Furuya, T.K.; Honjo, R.S.; Malaquias, A.C.; Bertola, D.R.; Costa, S.S.; Canton, A.P.; Roela, R.A.; Freire, B.L.; et al. Recurrent Copy Number Variants Associated with Syndromic Short Stature of Unknown Cause. Horm. Res. Paediatr. 2018, 89, 13–21. [Google Scholar] [CrossRef] [PubMed]
- Rapaport, R.; Wit, J.M.; Savage, M.O. Growth failure: ‘idiopathic’ only after a detailed diagnostic evaluation. Endocr. Connect. 2021, 10, R125–R138. [Google Scholar] [CrossRef] [PubMed]
- Polidori, N.; Castorani, V.; Mohn, A.; Chiarelli, F. Deciphering short stature in children. Ann. Pediatr. Endocrinol. Metab. 2020, 25, 69–79. [Google Scholar] [CrossRef] [PubMed]
- Neri, G.; Boccuto, L.; Stevenson, R.G. (Eds.) Overgrowth Syndromes a Clinical Guide; Oxford University Press: New York, NY, USA, 2019. [Google Scholar]
- Venken, K.; Schuit, F.; Van Lommel, L.; Tsukamoto, K.; Kopchick, J.J.; Coschigano, K.; Ohlsson, C.; Movérare, S.; Boonen, S.; Bouillon, R.; et al. Growth without growth hormone receptor: Estradiol is a major growth hormone-independent regulator of hepatic IGF-I synthesis. J. Bone Miner. Res. 2005, 20, 2138–2149. [Google Scholar] [CrossRef] [PubMed]
- Stene, L.C.; Lernmark, A. Epidemiology and Pathogenesis of Type 1 Diabetes. In Transplantation of the Pancreas; Gruessner, R.W.G., Gruessner, A.C., Eds.; Springer: Cham, Switzerland, 2023; pp. 13–39. [Google Scholar]
- Jebeile, H.; Kelly, A.S.; O’Mally, G.; Baur, L.A. Obesity in children and adolescents: Epidemiology, causes, assessment, and management. Lancet Diabetes Endocrinol. 2022, 10, 351–365. [Google Scholar] [CrossRef] [PubMed]
- Laron, Z.; Hampe, C.S.; Shulman, L.M. The urgent need to prevent type 1 autoimmune childhood diabetes. Pediatr. Endocrinol. Rev. 2015, 12, 266–282. [Google Scholar] [PubMed]
- Rosenthal, S.M. Transgender youth: Current concepts. Ann. Pediatr. Endocrinol. Metab. 2016, 21, 185–192. [Google Scholar] [CrossRef] [PubMed]
- Vrouenraets, L.J.; de Vries, A.L.; Arnoldussen, M.; Hannema, S.E.; Lindauer, R.J.; de Vries, M.C.; Hein, I.M. Medical decision-making competence regarding puberty suppression: Perceptions of transgender adolescents, their parents and clinicians. Eur. Child Adolesc. Psychiatry 2023, 32, 2343–2361. [Google Scholar] [CrossRef] [PubMed]
- Wisniewski, A.B.; Chernausek, S.D.; Kropp, B.P. Disorders of Sex Development, A Guide for Parents and Physicians; The Johns Hopkins University Press: Baltimore, MD, USA, 2012. [Google Scholar]
- Miller, B.S. What do we do now that the long-acting growth hormone is here? Front. Endocrinol. 2022, 13, 980979. [Google Scholar] [CrossRef] [PubMed]
- Galetaki, D.M.; Merchant, N.; Dauber, A. Novel therapies for growth disorders. Eur. J. Pediatr. 2023, 1–8. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Laron, Z. Challenges in Pediatric Endocrinology. Children 2023, 10, 1757. https://doi.org/10.3390/children10111757
AMA Style
Laron Z. Challenges in Pediatric Endocrinology. Children. 2023; 10(11):1757. https://doi.org/10.3390/children10111757
Chicago/Turabian StyleLaron, Zvi. 2023. "Challenges in Pediatric Endocrinology" Children 10, no. 11: 1757. https://doi.org/10.3390/children10111757
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
